Evidence map›Paper›PMID 26944362›Full record

SynthesisTherapeutic advances in respiratory disease2016

Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Omar Abdel-Rahman, Mona Fouad

Abstract readComparative StudyMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Therapeutic advances in respiratory disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2019
    Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Pulmonary toxicity of immune checkpoint immunotherapy.The Journal of clinical investigation · 2024
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Omar Abdel-RahmanClinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, Cairo 11665, Egypt omar.abdelrhman@med.asu.edu.eg.
Mona FouadMedical Microbiology and Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA meta-analysis of the risk of pneumonitis associated with the use of immune checkpoint inhibitors in cancer patients has been conducted.

methodsEligible publications included randomized trials of cancer patients on immune checkpoint inhibitors, describing events of all-grade and high-grade pneumonitis.

resultsAfter exclusion of noneligible citations, a total of 11 clinical trials were eligible for the meta-analysis. The odds ratio was 3.96 [95% confidence interval (CI): 2.02-7.79; p < 0.0001] for all-grade pneumonitis and 2.87 (95% CI: 0.90-9.20; p = 0.08) for high-grade pneumonitis. Moreover, the odds ratio of all-grade pneumonitis with a nivolumab/ipilimumab combination versus ipilimumab monotherapy was 3.68 (95% CI: 1.59-8.50; p = 0.002) and, for high-grade pneumonitis, it was 1.86(95% CI: 0.36-9.53; p = 0.46). Subgroup analysis did not reveal a difference between lung cancer patients and other cancer patients in the risk of pneumonitis.

conclusionsOur analysis provided evidence that the use of immune checkpoint inhibitors is associated with an increased risk of all-grade pneumonitis compared with chemotherapy or placebo controls.

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsHumansIpilimumabNeoplasmsNivolumabPneumoniaRandomized Controlled Trials as TopicRiskAntibodies, MonoclonalAntineoplastic AgentsIpilimumabNivolumabipilimumabnivolumabNSCLCpembrolizumabpneumonitis

Identifiers

PMID26944362
PMCPMC5933609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.